Animal Models of Cystic Fibrosis Pathology: Phenotypic Parallels and Divergences

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Lavelle, Gillian M ^a   White, Michelle M ^a   Browne, Niall ^a   McElvaney, Noel G ^a   Reeves, Emer P ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL SODIUM CHANNEL; IVACAFTOR; LUMACAFTOR;

ARTICLE; CYSTIC FIBROSIS; ENTEROPATHY; FERRET; FERTILITY; FORCED EXPIRATORY VOLUME; GENE MUTATION; HEPATOBILIARY DISEASE; HUMAN; MEMBRANE CHANNEL; NONHUMAN; PANCREAS DISEASE; PATHOPHYSIOLOGY; PHENOTYPE; RESPIRATORY TRACT DISEASE; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; GENETICS; INFLAMMATION; MOUSE; MUSTELA PUTORIUS FURO; NEUTROPHIL; PATHOLOGY; PIG;

ANIMALS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DISEASE MODELS, ANIMAL; FERRETS; HUMANS; INFLAMMATION; MICE; NEUTROPHILS; SWINE;

EID: 84975257314     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/5258727     Document Type: Article

References (119)

1. K. Yoshimura, H. Nakamura, B. C. Trapnell et al., "Expressionof the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin," Nucleic Acids Research, vol. 19, no. 19, pp. 5417-5423, 1991.
2. J. R. Riordan, J. M. Rommens, B.-S. Kerem et al., "Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA," Science, vol. 245, no. 4922, pp. 1066-1073, 1989.
3. The Cystic Fibrosis Registry of Ireland, 2012 Annual Report, The Cystic Fibrosis Registry of Ireland, Dublin, Ireland, 2012.
4. Cystic Fibrosis Foundation, Patient Registry-Annual Data Report 2012, Cystic Fibrosis Foundation, Bethesda, Md, USA, 2012.
5. L. Zhang, B. Button, S.E. Gabriel et al., "CFTRdelivery to25%of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium," PLoS Biology, vol. 7, no. 7, Article ID e1000155, 2009.
6. D. S. Armstrong, K. Grimwood, J. B. Carlin et al., "Lower airway inflammation in infants and young children with cystic fibrosis," American Journal of Respiratory and Critical Care Medicine, vol. 156, no. 4, pp. 1197-1204, 1997.
7. M. W. Konstan, K. A. Hilliard, T. M. Norvell, and M. Berger, "Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation," American Journal of Respiratory and Critical Care Medicine, vol. 150, no. 2, pp. 448-454, 1994.
8. R. C. Boucher, "New concepts of the pathogenesis of cystic fibrosis lung disease," European Respiratory Journal, vol. 23, no. 1, pp. 146-158, 2004.
9. Y. Gernez, C. E. Dunn, C. Everson et al., "Blood basophils from cystic fibrosis patients with allergic bronchopulmonary aspergillosis are primed and hyper-responsive to stimulation by aspergillus allergens," Journal of Cystic Fibrosis, vol. 11, no. 6, pp. 502-510, 2012.
10. H.P. J. van der Doef, F. T.M. Kokke, C. K. van der Ent, and R.H. J. Houwen, "Intestinal obstruction syndromes in cystic fibrosis: meconium ileus, distal intestinal obstruction syndrome, and constipation," Current Gastroenterology Reports, vol. 13, no. 3, pp. 265-270, 2011.
11. T. Kelly and J. Buxbaum, "Gastrointestinal manifestations of cystic fibrosis," Digestive Diseases and Sciences, vol. 60, no. 7, pp. 1903-1913, 2015.
12. The Cystic Fibrosis Registry of Ireland, 2013 Annual Report, The Cystic Fibrosis Registry of Ireland, Dublin, Ireland, 2013.
13. S. M. Moskowitz, J. F. Chmiel, D. L. Sternen et al., "Clinical practice and genetic counseling for cystic fibrosis and CFTRrelated disorders," Genetics in Medicine, vol. 10, no. 12, pp. 851-868, 2008.
14. P. Y.D. Wong, "CFTR gene andmale fertility," Molecular Human Reproduction, vol. 4, no. 2, pp. 107-110, 1998.
15. J. T. Fisher, Y. Zhang, and J. F. Engelhardt, "Comparative biology of cystic fibrosis animal models," Methods in Molecular Biology, vol. 742, pp. 311-334, 2011.
16. C. S. Rogers, Y. Hao, T. Rokhlina et al., "Production of CFTRnull and CFTR-ΔF508 heterozygous pigs by adeno-associated virus-mediated gene targeting and somatic cell nuclear transfer," The Journal of Clinical Investigation, vol. 118, no. 4, pp. 1571-1577, 2008.
17. D. A. Stoltz, D. K. Meyerholz, A. A. Pezzulo et al., "Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth," Science Translational Medicine, vol. 2, no. 29, Article ID29ra31, 18 pages, 2010.
18. X. Sun, H. Sui, J. T. Fisher et al., "Disease phenotype of a ferret CFTR-knockoutmodel of cystic fibrosis," The Journal of Clinical Investigation, vol. 120, no. 9, pp. 3149-3160, 2010.
19. X. Sun, A. K. Olivier, B. Liang et al., "Lung phenotype of juvenile and adult cystic fibrosis transmembrane conductance regulatorknockout ferrets," American Journal of Respiratory Cell and Molecular Biology, vol. 50, no. 3, pp. 502-512, 2014.
20. N.W. Keiser, S. E. Birket, I. A. Evans et al., "Defective innate immunity and hyperinflammation in newborn cystic fibrosis transmembrane conductance regulator-knockout ferret lungs," American Journal of Respiratory Cell and Molecular Biology, vol. 52, no. 6, pp. 683-694, 2015.
21. J. J. Smith, P. H. Karp, and M. J. Welsh, "Defective fluid transport by cystic fibrosis airway epithelia," The Journal of Clinical Investigation, vol. 93, no. 3, pp. 1307-1311, 1994.
22. J. B. Lyczak, C. L. Cannon, and G. B. Pier, "Lung infections associated with cystic fibrosis," Clinical Microbiology Reviews, vol. 15, no. 2, pp. 194-222, 2002.
23. + absorption produces cystic fibrosis-like lung disease in mice," Nature Medicine, vol. 10, no. 5, pp. 487-493, 2004.
24. S. Haerteis, B. Krueger, C. Korbmacher, and R. Rauh, "The δ-subunit of the epithelial sodium channel (ENaC) enhances channel activity and alters proteolytic ENaC activation," The Journal of Biological Chemistry, vol. 284, no. 42, pp. 29024-29040, 2009.
25. R. Waldmann, G. Champigny, F. Bassilana, N. Voilley, and M. Lazdunski, "Molecular cloning and functional expression of a novel amiloride-sensitive Na+ channel," Journal of Biological Chemistry, vol. 270, no. 46, pp. 27411-27414, 1995.
26. M. Althaus, "ENaC inhibitors and airway re-hydration in cystic fibrosis: state of the art," Current Molecular Pharmacology, vol. 6, no. 1, pp. 3-12, 2013.
27. K. Pohl, E. Hayes, J. Keenan et al., "Aneutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy," Blood, vol. 124, no. 7, pp. 999-1009, 2014.
28. M. B. Butterworth, "Regulation of the epithelial sodiumchannel (ENaC) by membrane trafficking," Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, vol. 1802, no. 12, pp. 1166-1177, 2010.
29. M. Lu, Q. Leng, M. E. Egan et al., "CFTR is required for PKAregulated ATP sensitivity of Kir1.1 potassium channels in mouse kidney," Journal of Clinical Investigation, vol. 116, no. 3, pp. 797-807, 2006.
30. D. J. M. Rommens, "Cystic Fibrosis Mutation Database," http://www.genet.sickkids.on.ca/Home.html.
31. E. Hayes, K. Pohl, N. G. McElvaney, and E.P. Reeves, "The cystic fibrosis neutrophil: a specialized yet potentially defective cell," Archivum Immunologiae et Therapiae Experimentalis, vol. 59, no. 2, pp. 97-112, 2011.
32. G. L. Lukacs, X.-B. Chang, C. Bear et al., "The ΔF508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane: determination of functional half-lives on transfected cells," Journal of Biological Chemistry, vol. 268, no. 29, pp. 21592-21598, 1993.
33. J. Bott, S. Blumenthal, M. Buxton et al., "Guidelines for the physiotherapy management of the adult, medical, spontaneously breathing patient," Thorax, vol. 64, no. 1, pp. i1-i52, 2009.
34. M. Robinson, A. L. Hemming, J. A. Regnis et al., "Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis," Thorax, vol. 52, no. 10, pp. 900-903, 1997.
35. P. Wark and V. M. McDonald, "Nebulised hypertonic saline for cystic fibrosis," Cochrane Database of Systematic Reviews, vol. 2, Article ID CD001506, 2009.
36. E. P. Reeves, M. Williamson, S. J. O'Neill, P. Greally, and N. G. McElvaney, "Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis," American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 11, pp. 1517-1523, 2011.
37. F. Christopher, D. Chase, K. Stein, and R. Milne, "rhDNase therapy for the treatment of cystic fibrosis patients with mild to moderate lung disease," Journal of Clinical Pharmacy and Therapeutics, vol. 24, no. 6, pp. 415-426, 1999.
38. M. Hofer, C. Benden, I. Inci et al., "True survival benefit of lung transplantation for cystic fibrosis patients: the Zurich experience," The Journal of Heart and Lung Transplantation, vol. 28, no. 4, pp. 334-339, 2009.
39. F. J. Accurso, S. M. Rowe, J. P. Clancy et al., "Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation," The New England Journal of Medicine, vol. 363, no. 21, pp. 1991-2003, 2010.
40. B. W. Ramsey, J. Davies, N. G. McElvaney et al., "A CFTR potentiator in patients with cystic fibrosis and the G551D mutation," The New England Journal of Medicine, vol. 365, no. 18, pp. 1663-1672, 2011.
41. S. M. Rowe, S. L. Heltshe, T. Gonska et al., "Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis," American Journal of Respiratory and Critical Care Medicine, vol. 190, no. 2, pp. 175-184, 2014.
42. L. R. Reznikov, M. H. Abou Alaiwa, C. L. Dohrn et al., "Antibacterial properties of the CFTR potentiator ivacaftor," Journal of Cystic Fibrosis, vol. 13, no. 5, pp. 515-519, 2014.
43. P. E. Bratcher, S.M. Rowe, G. Reeves et al., "Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor," Journal of Cystic Fibrosis, vol. 15, no. 1, pp. 67-73, 2016.
44. P. A. Flume, T. G. Liou, D. S. Borowitz et al., "Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation," Chest, vol. 142, no. 3, pp. 718-724, 2012.
45. Vertex Pharmaceuticals Incorporated Report, "Two 24-Week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation," 2014.
46. C. E. Wainwright, J. S. Elborn, B.W. Ramsey et al., "Lumacaftorivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR," The New England Journal of Medicine, vol. 373, no. 3, pp. 220-231, 2015.
47. FDA, "FDA approves new treatment for cystic fibrosis," http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453565.htm.
48. B.-S. Kerem, J. M. Rommens, J. A. Buchanan et al., "Identification of the cystic fibrosis gene: genetic analysis," Science, vol. 245, no. 4922, pp. 1073-1080, 1989.
49. J. N. Snouwaert, K. K. Brigman, A. M. Latour et al., "An animal model for cystic fibrosis made by gene targeting," Science, vol. 257, no. 5073, pp. 1083-1088, 1992.
50. D. J. Davidson and J. R. Dorin, "The CF mouse: an important tool for studying cystic fibrosis," Expert Reviews in Molecular Medicine, vol. 3, pp. 1-27, 2004.
51. R. Ratcliff, M. J. Evans, A. W. Cuthbert et al., "Production of a severe cystic fibrosis mutation in mice by gene targeting," Nature Genetics, vol. 4, no. 1, pp. 35-41, 1993.
52. W. K. O'Neal, P. Hasty, P. B. McCray Jr. et al., "A severe phenotype in mice with a duplication of exon 3 in the cystic fibrosis locus," Human Molecular Genetics, vol. 2, no. 10, pp. 1561-1569, 1993.
53. P. Hasty, W. K. O'Neal, K.-Q. Liu et al., "Severe phenotype in mice with termination mutation in exon 2 of cystic fibrosis gene," Somatic Cell and Molecular Genetics, vol. 21, no. 3, pp. 177-187, 1995.
54. R. Rozmahel, M. Wilschanski, A. Matin et al., "Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor," Nature Genetics, vol. 12, no. 3, pp. 280-287, 1996.
55. J. H. van Doorninck, P. J. French, E. Verbeek et al., "A mouse model for the cystic fibrosis ΔF508 mutation," The EMBO Journal, vol. 14, no. 18, pp. 4403-4411, 1995.
56. B. G. Zeiher, E. Eichwald, J. Zabner et al., "A mouse model for the delta F508 allele of cystic fibrosis," The Journal of Clinical Investigation, vol. 96, no. 4, pp. 2051-2064, 1995.
57. W. H. Colledge, B. S. Abella, K.W. Southern et al., "Generation and characterization of a ΔF508 cystic fibrosis mouse model," Nature Genetics, vol. 10, no. 4, pp. 445-452, 1995.
58. P. Dickinson, S. N. Smith, S. Webb et al., "The severe G480C cystic fibrosis mutation, when replicated in the mouse, demonstrates mistrafficking, normal survival and organ-specific bioelectrics," Human Molecular Genetics, vol. 11, no. 3, pp. 243-251, 2002.
59. S. J. Delaney, E.W. F.W. Alton, S. N. Smith et al., "Cystic fibrosis mice carrying the missense mutation G551D replicate human genotype-phenotype correlations," The EMBO Journal, vol. 15, no. 5, pp. 955-963, 1996.
60. J. R. Dorin, P. Dickinson, E.W. F.W. Alton et al., "Cystic fibrosis in the mouse by targeted insertional mutagenesis," Nature, vol. 359, no. 6392, pp. 211-215, 1992.
61. J. R. Dorin, P. Dickinson, E. Emslie et al., "Successful targeting of the mouse cystic fibrosis transmembrane conductance regulator gene in embryonal stem cells," Transgenic Research, vol. 1, no. 2, pp. 101-105, 1992.
62. C. Guilbault, Z. Saeed, G. P. Downey, and D. Radzioch, "Cystic fibrosis mouse models," American Journal of Respiratory Cell and Molecular Biology, vol. 36, no. 1, pp. 1-7, 2007.
63. D. J. Davidson and M. Rolfe, "Mouse models of cystic fibrosis," Trends in Genetics, vol. 17, no. 10, pp. S29-S37, 2001.
64. M. Wilke, R. M. Buijs-Offerman, J. Aarbiou et al., "Mouse models of cystic fibrosis: phenotypic analysis and research applications," Journal of Cystic Fibrosis, vol. 10, no. 2, pp. S152-S171, 2011.
65. B. Johannesson, S. Hirtz, J. Schatterny, C. Schultz, and M. A. Mall, "CFTR regulates early pathogenesis of chronic obstructive lung disease in βenac-overexpressing mice," PLoS ONE, vol. 7, no. 8, article e44059, 2012.
66. H. Ma and Y. Yang, "Epithelial sodiumchannel (ENaC)," Journal of American Science, vol. 5, no. 6, pp. 62-69, 2009.
67. M. E. Egan, "How useful are cystic fibrosis mouse models?" Drug Discovery Today: Disease Models, vol. 6, no. 2, pp. 35-41, 2009.
68. L. L. Clarke, B. R. Grubb, J. R. Yankaskas, C. U. Cotton, A. McKenzie, and R. C. Boucher, "Relationship of a noncystic fibrosis transmembrane conductance regulator-mediated chloride conductance to organ-level disease in CFTR(-/-) mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 2, pp. 479-483, 1994.
69. D. Gosselin, M. M. Stevenson, E. A. Cowley et al., "Impaired ability of CFTR knockout mice to control lung infection with Pseudomonas aeruginosa," American Journal of Respiratory and Critical Care Medicine, vol. 157, no. 4, part 1, pp. 1253-1262, 1998.
70. -/- mice," Infection and Immunity, vol. 69, no. 8, pp. 5138-5150, 2001.
71. A. Van Heeckeren, R. Walenga, M. W. Konstan, T. Bonfield, P. B. Davis, and T. Ferkol, "Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa," The Journal of Clinical Investigation, vol. 100, no. 11, pp. 2810-2815, 1997.
72. V. S. Shah, D. K. Meyerholz, X. X. Tang et al., "Airway acidification initiates host defense abnormalities in cystic fibrosis mice," Science, vol. 351, no. 6272, pp. 503-507, 2016.
73. S. Gehrig, J. Duerr, M. Weitnauer et al., "Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosislike lung disease," American Journal of Respiratory and Critical Care Medicine, vol. 189, no. 9, pp. 1082-1092, 2014.
74. D. Borowitz and D. Gelfond, "Intestinal complications of cystic fibrosis," Current Opinion in Pulmonary Medicine, vol. 19, no. 6, pp. 676-680, 2013.
75. N. W. Keiser and J. F. Engelhardt, "New animal models of cystic fibrosis: what are they teaching us?" Current Opinion in Pulmonary Medicine, vol. 17, no. 6, pp. 478-483, 2011.
76. S. M. Rowe, S. Miller, and E. J. Sorscher, "Cystic fibrosis," The New England Journal of Medicine, vol. 352, no. 19, pp. 1992-2001, 2005.
77. J. R. Dorin, B. J. Stevenson, S. Fleming, E. W. F. W. Alton, P. Dickinson, and D. J. Porteous, "Long-term survival of the exon 10 insertional cystic fibrosis mutant mouse is a consequence of low level residual wild-type CFTR gene expression," Mammalian Genome, vol. 5, no. 8, pp. 465-472, 1994.
78. P. G. Noone and M. R. Knowles, "'CFTR-opathies': disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations," Respiratory Research, vol. 2, no. 6, pp. 328-332, 2001.
79. A. Y. H. Leung, P. Y. D. Wong, J. R. Yankaskas, and R. C. Boucher, "cAMP-but not Ca(2+)-regulated Cl-conductance is lacking in cystic fibrosis mice epididymides and seminal vesicles," American Journal of Physiology-Cell Physiology, vol. 271, no. 1, part 1, pp. C188-C193, 1996.
80. C. A. Hodges, M. R. Palmert, and M. L. Drumm, "Infertility in females with cystic fibrosis is multifactorial: evidence from mouse models," Endocrinology, vol. 149, no. 6, pp. 2790-2797, 2008.
81. M. Du, X. Liu, E. M. Welch, S. Hirawat, S. W. Peltz, and D. M. Bedwell, "PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 6, pp. 2064-2069, 2008.
82. X. Xue, V. Mutyam, L. Tang et al., "Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor," American Journal of Respiratory Cell and Molecular Biology, vol. 50, no. 4, pp. 805-816, 2014.
83. R. Robert, G. W. Carlile, J. Liao et al., "Correction of the ΔPhe508 cystic fibrosis transmembrane conductance regulator trafficking defect by the bioavailable compound glafenine," Molecular Pharmacology, vol. 77, no. 6, pp. 922-930, 2010.
84. S. Noël, M. Wilke, A. G. M. Bot, H. R. De Jonge, and F. Becq, "Parallel improvement of sodium and chloride transport defects by miglustat (n-butyldeoxynojyrimicin) in cystic fibrosis epithelial cells," Journal of Pharmacology and Experimental Therapeutics, vol. 325, no. 3, pp. 1016-1023, 2008.
85. D. Vidović, M. S. Carlon, M. F. da Cunha et al., "rAAVCFTRΔR rescues the cystic fibrosis phenotype in human intestinal organoids and cystic fibrosis mice," American Journal of Respiratory and Critical Care Medicine, vol. 193, no. 3, pp. 288-298, 2016.
86. M. A. Mall and L. J.V. Galietta, "Targeting ion channels in cystic fibrosis," Journal of Cystic Fibrosis, vol. 14, no. 5, pp. 561-570, 2015.
87. L. S. Ostedgaard, D. K. Meyerholz, J.-H. Chen et al., "The ΔF508 mutation causes CFTR misprocessing and cystic fibrosis-like disease in pigs," Science Translational Medicine, vol. 3, no. 74, Article ID 74ra24, pp. 1-24, 2011.
88. D. A. Stoltz, T. Rokhlina, S. E. Ernst et al., "Intestinal CFTR expression alleviates meconium ileus in cystic fibrosis pigs," The Journal of Clinical Investigation, vol. 123, no. 6, pp. 2685-2693, 2013.
89. C. S. Rogers, D. A. Stoltz, D. K. Meyerholz et al., "Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs," Science, vol. 321, no. 5897, pp. 1837-1841, 2008.
90. K. O. McKay, B. R. Wiggs, P. D. Paré, and R. D. Kamm, "Zero-stress state of intra- and extraparenchymal airways from human, pig, rabbit, and sheep lung," Journal of Applied Physiology, vol. 92, no. 3, pp. 1261-1266, 2002.
91. J. N. Maina and P. Van Gils, "Morphometric characterization of the airway and vascular systems of the lung of the domestic pig, Sus scrofa: comparison of the airway, arterial and venous systems," Comparative Biochemistry and Physiology-A Molecular and Integrative Physiology, vol. 130, no. 4, pp. 781-798, 2001.
92. P. Bradley, F. J. Bourne, and P. Brown, "The respiratory tract immune system in the pig," Veterinary Pathology, vol. 13, no. 2, pp. 90-97, 1976.
93. D. K. Meyerholz, D. A. Stoltz, E. Namati et al., "Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children," American Journal of Respiratory and Critical Care Medicine, vol. 182, no. 10, pp. 1251-1261, 2010.
94. R. J. Adam, A. S. Michalski, C. Bauer et al., "Air trapping and airflow obstruction in newborn cystic fibrosis piglets," American Journal of Respiratory and Critical Care Medicine, vol. 188, no. 12, pp. 1434-1441, 2013.
95. M. Rosenfeld, R. L. Gibson, S. McNamara et al., "Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis," Pediatric Pulmonology, vol. 32, no. 5, pp. 356-366, 2001.
96. J. L. Burns, R. L. Gibson, S. McNamara et al., "Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis," Journal of Infectious Diseases, vol. 183, no. 3, pp. 444-452, 2001.
97. T. Z. Khan, J. S. Wagener, T. Bost, J. Martinez, F. J. Accurso, and D.W. H. Riches, "Early pulmonary inflammation in infants with cystic fibrosis," American Journal of Respiratory and Critical Care Medicine, vol. 151, no. 4, pp. 1075-1082, 1995.
98. J.-H. Chen, D. A. Stoltz, P. H. Karp et al., "Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia," Cell, vol. 143, no. 6, pp. 911-923, 2010.
99. T. A. Standaert, L. Boitano, J. Emerson et al., "Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials," Pediatric Pulmonology, vol. 37, no. 5, pp. 385-392, 2004.
100. J. C. Davies, M. Davies, D. McShane et al., "Potential difference measurements in the lower airway of children with and without cystic fibrosis," American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 9, pp. 1015-1019, 2005.
101. D. K. Meyerholz, D. A. Stoltz, A. A. Pezzulo, and M. J. Welsh, "Pathology of gastrointestinal organs in a porcine model of cystic fibrosis," American Journal of Pathology, vol. 176, no. 3, pp. 1377-1389, 2010.
102. S. M. Blackman, R. Deering-Brose, R. McWilliams et al., "Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis," Gastroenterology, vol. 131, no. 4, pp. 1030-1039, 2006.
103. E. C. Benya, A. R. Nussbaum-Blask, and D. M. Selby, "Colonic diverticulitis causing partial bowel obstruction in a child with cystic fibrosis," Pediatric Radiology, vol. 27, no. 12, pp. 918-919, 1997.
104. B. P. O'Sullivan, D. Baker, K. G. Leung, G. Reed, S. S. Baker, and D. Borowitz, "Evolution of pancreatic function during the first year in infants with cystic fibrosis," Journal of Pediatrics, vol. 162, no. 4, pp. 808-812.e1, 2013.
105. A. Uc, R. Giriyappa, D. K. Meyerholz et al., "Pancreatic and biliary secretion are both altered in cystic fibrosis pigs," American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 303, no. 8, pp. G961-G968, 2012.
106. K. N. Lazaridis, M. Strazzabosco, and N. F. Larusso, "The cholangiopathies: disorders of biliary epithelia," Gastroenterology, vol. 127, no. 5, pp. 1565-1577, 2004.
107. L. Vítek and M. C. Carey, "Enterohepatic cycling of bilirubin as a cause of 'black' pigment gallstones in adult life," European Journal of Clinical Investigation, vol. 33, no. 9, pp. 799-810, 2003.
108. D. P. Cook, M. V. Rector, D. C. Bouzek et al., "Cystic fibrosis transmembrane conductance regulator in sarcoplasmic reticulum of airway smooth muscle. Implications for airway contractility," American Journal of Respiratory and Critical Care Medicine, vol. 193, no. 4, pp. 417-426, 2016.
109. M. E. R. Darnell, E. P. Plant, H. Watanabe et al., "Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets," The Journal of Infectious Diseases, vol. 196, no. 9, pp. 1329-1338, 2007.
110. F. Krammer, R. Hai, M. Yondola et al., "Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets," Journal of Virology, vol. 88, no. 6, pp. 3432-3442, 2014.
111. J. F. Engelhardt, J. R. Yankaskas, S. A. Ernst et al., "Submucosal glands are the predominant site of CFTR expression in the human bronchus," Nature Genetics, vol. 2, no. 3, pp. 240-248, 1992.
112. R. Dajani, Y. Zhang, P. J. Taft et al., "Lysozyme secretion by submucosal glands protects the airway from bacterial infection," American Journal of Respiratory Cell and Molecular Biology, vol. 32, no. 6, pp. 548-552, 2005.
113. X. Liu, M. Luo, L. Zhang, W. Ding, Z. Yan, and J. F. Engelhardt, "Bioelectric properties of chloride channels in human, pig, ferret, and mouse airway epithelia," American Journal of Respiratory Cell and Molecular Biology, vol. 36, no. 3, pp. 313-323, 2007.
114. X. Sun, Z. Yan, Y. Yi et al., "Adeno-associated virus-targeted disruption of the CFTR gene in cloned ferrets," Journal of Clinical Investigation, vol. 118, no. 4, pp. 1578-1583, 2008.
115. C. A. Johnson-Delaney, "Ferret nutrition," Veterinary Clinics of North America: Exotic Animal Practice, vol. 17, no. 3, pp. 449-470, 2014.
116. D. H. Andersen, "Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study," American Journal of Diseases of Children, vol. 56, no. 2, pp. 344-399, 1938.
117. R. W. Shepherd and G. J. Cleghorn, Cystic Fibrosis: Nutritional and Intestinal Disorders, CRC Press, New York, NY, USA, 1989.
118. W. Lissens, B. Mercier, H. Tournaye et al., "Cystic fibrosis and infertility caused by congenital bilateral absence of the vas deferens and related clinical entities," Human Reproduction, vol. 11, no. 4, pp. 55-80, 1996.
119. D. A. Gaillard, F. Carre-Pigeon, and A. Lallemand, "Normal vas deferens in fetuses with cystic fibrosis," Journal of Urology, vol. 158, no. 4, pp. 1549-1552, 1997.